In Silico trials for drug tracing the effects of sarcomeric protein mutations leading to familial cardiomyopathy

Project: Research

Project Details


The EU Horizon 2020 funded SILICOFCM project ( will develop a computational platform for in silico clinical trials for familial cardiomyopathies capable of optimizing and testing medical treatment strategies to improve patients outcomes. As a Chief Investigator of a clinical workpackage, Professor Jakovljevic leads an international multicentre phase II clinical trial "Sacubitril/valsartan vs lifestyle in hypertrophic cardiomyopathy" (
Total project value €5,559,201.
Short titleSacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy
Effective start/end date1/06/1828/02/22

Collaborative partners

  • Coventry University
  • Newcastle University (Project partner)
  • University of Kent (Project partner)
  • University Hospital Regensburg (Project partner)
  • University of Kragujevac (Project partner)
  • Careggi University Hospital (Project partner)
  • University of Belgrade (Project partner)
  • Washington State University (Project partner)
  • Illinois Institute of Technology (Project partner)
  • Seven Bridges Genomics (Project partner)
  • Barcelona Supercomputing Center (Project partner)
  • University of Ioannina (Project partner)
  • University of Ljubljana (Project partner)
  • BIOIRC - Bioengineering Research and Development Center (lead)
  • University of Novi Sad (Project partner)
  • Steinbeis Advanced Risk Technologies Gmbh R-Tech (Project partner)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.